The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.
作者信息
Pessoa-Amorim Guilherme, Mafham Marion M
机构信息
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
出版信息
Cardiovasc Res. 2021 Jul 27;117(9):e110-e113. doi: 10.1093/cvr/cvab239.
Abstract
摘要
相似文献
1
The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.RECOVERY试验：一项针对COVID-19的大型简单随机试验的心血管影响
Cardiovasc Res. 2021 Jul 27;117(9):e110-e113. doi: 10.1093/cvr/cvab239.
2
The Evolution of Antithrombotic Care in Cardiovascular Patients.
Thromb Haemost. 2018 May;118(S 01):S1. doi: 10.1055/s-0038-1626720. Epub 2018 Mar 22.
3
Cardiac surgery in patients on antiplatelet and antithrombotic agents.
Semin Thorac Cardiovasc Surg. 2005 Spring;17(1):66-72. doi: 10.1053/j.semtcvs.2005.01.001.
4
Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19.用于预防和管理新型冠状病毒肺炎血栓形成的药物治疗
Semin Thromb Hemost. 2020 Oct;46(7):789-795. doi: 10.1055/s-0040-1714273. Epub 2020 Aug 20.
5
Is the type of diabetes treatment relevant to outcome of COVID-19?糖尿病治疗类型与新型冠状病毒肺炎的预后有关吗？
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
6
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease.东亚悖论：心血管疾病患者当前抗栓策略面临挑战的最新立场声明。
Thromb Haemost. 2021 Apr;121(4):422-432. doi: 10.1055/s-0040-1718729. Epub 2020 Nov 10.
7
Cardiovascular disease due to novel coronavirus and the search for investigational therapies.新型冠状病毒引起的心血管疾病与探索性治疗方法。
J Vasc Surg. 2021 Jan;73(1):13-17. doi: 10.1016/j.jvs.2020.04.503. Epub 2020 May 17.
8
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.针对 COVID-19 的血栓炎症的药物靶点：综述及对未来研究的启示。
Thromb Haemost. 2020 Jul;120(7):1004-1024. doi: 10.1055/s-0040-1713152. Epub 2020 May 30.
9
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.血管紧张素受体阻滞剂的作用已不仅限于降血压。
Physiology (Bethesda). 2021 May 1;36(3):160-173. doi: 10.1152/physiol.00036.2020.
10
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.评价在 ClinicalTrials.gov 上注册的心血管治疗 COVID-19 的临床试验特征：一项横断面分析。
Am Heart J. 2021 Feb;232:105-115. doi: 10.1016/j.ahj.2020.10.065. Epub 2020 Oct 26.
引用本文的文献
1
Effects of colchicine, interferon β, IVIG, tocilizumab and corticosteroids on COVID-19 patient survival from all presently available published clinical trials: A narrative review.秋水仙碱、干扰素β、静脉注射免疫球蛋白、托珠单抗和皮质类固醇对COVID-19患者生存的影响：基于所有现有已发表临床试验的叙述性综述。
Caspian J Intern Med. 2025 Mar 11;16(2):198-214. doi: 10.22088/cjim.16.2.198. eCollection 2025.
2
COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas.新冠病毒肺炎与心律失常：经验教训与困境
J Clin Med. 2024 Nov 29;13(23):7259. doi: 10.3390/jcm13237259.
3
The complexity of cardiovascular long COVID: where we are.心血管长期新冠的复杂性：我们目前的状况
Cardiovasc Res. 2024 Jul 2;120(8):e30-e32. doi: 10.1093/cvr/cvae090.
4
Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method.使用新型机器学习方法识别治疗新冠病毒病的合适药物组合：RAIN方法
Life (Basel). 2022 Sep 19;12(9):1456. doi: 10.3390/life12091456.
本文引用的文献
1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
2
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.羟氯喹和氯喹治疗 COVID-19 的国际合作随机试验荟萃分析的死亡率结果。
Nat Commun. 2021 Apr 15;12(1):2349. doi: 10.1038/s41467-021-22446-z.
3
COVID-19 and its cardiovascular effects: a systematic review of prevalence studies.COVID-19 及其心血管影响：患病率研究的系统综述。
Cochrane Database Syst Rev. 2021 Mar 11;3(3):CD013879. doi: 10.1002/14651858.CD013879.
4
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 患者住院期间使用阿奇霉素（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5. Epub 2021 Feb 2.
5
Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis.使用 18F-氟代脱氧葡萄糖正电子发射断层扫描监测托珠单抗对巨细胞动脉炎血管炎症的作用。
Rheumatology (Oxford). 2021 Sep 1;60(9):4384-4389. doi: 10.1093/rheumatology/keaa894.
6
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
7
Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis.COVID-19 住院患者的生物标志物和结局：系统评价和荟萃分析。
BMJ Evid Based Med. 2021 Jun;26(3):107-108. doi: 10.1136/bmjebm-2020-111536. Epub 2020 Sep 15.
8
Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.SARS-CoV-2 与 ACE2 受体结合的分子相互作用和抑制。
Nat Commun. 2020 Sep 11;11(1):4541. doi: 10.1038/s41467-020-18319-6.
9
Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis.心血管疾病与其他 10 种预先存在的合并症与 COVID-19 死亡率的关联：系统评价和荟萃分析。
PLoS One. 2020 Aug 26;15(8):e0238215. doi: 10.1371/journal.pone.0238215. eCollection 2020.
10
An inflammatory cytokine signature predicts COVID-19 severity and survival.炎症细胞因子特征可预测 COVID-19 严重程度和存活情况。
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.
Zotero 插件